The FDA is currently undergoing significant upheaval as the agency grapples with the departure of several high-profile officials, including Richard Pazdur, the top drug regulator. This leadership shake-up, described by some scientists as "rocking the agency like an atom bomb," has raised alarms regarding the direction and stability of the FDA. Concerns have intensified following the exit of veteran cancer researcher Pazdur and the subsequent appointment of Tracy Beth Høeg as acting director of the drug evaluation center. Critics, including former agency leaders and industry representatives, are urging the FDA to address its ongoing turmoil, which they fear could threaten public health and hinder biotech recovery. The situation reflects a broader crisis within the agency that has seen unprecedented changes in leadership, with executives citing feelings of being undercut and a lack of direction in drug approval processes. This instability is viewed as a tipping point for the FDA, prompting calls for immediate action to restore credibility and leadership within the agency.